Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
22.79%
Operating Margin
8.34%
Net Margin
-3.65%
Efficiency Metrics
Revenue per Expense Ratio
1.09
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
20.92%
Income Tax Rate
268,900,000.0%
EPS
-1.1300000000
Balance Sheet Analysis
Current Ratio
1.43
Cash Ratio
1.00
Working Capital
$72.23M
Debt to Equity
1.54
Debt to Assets
54.91%
Equity Ratio
35.70%
Cash Flow Analysis
Operating Cash Flow Ratio
11.46%
Free Cash Flow Ratio
1.03%
CapEx to Revenue
10.43%
Dividends Paid
$52.56M
Stock Buybacks
$29.13M
Total Shareholder Returns
$81.69M
Cash Position Change
-47.26%
Key Takeaways (2023 FY)
Increased dividend payments by 167.34%
Detailed Growth Metrics
Core Performance
Revenue
10.42%
Net Income
-252.11%
EPS
-653.33%
Operating Income
-9.83%
Operational Efficiency
R&D Expenses
-100.00%
SG&A Expenses
-52.86%
Operating Cash Flow
-22.63%
Free Cash Flow
40.28%
Balance Sheet Health
Assets
-7.13%
Debt
-12.33%
Book Value per Share
4.65%
Inventory
-4.49%
Shareholder Returns
Dividends per Share
167.34%
Shares Outstanding
-5.31%
Long Term Trends
3Y Revenue/Share
67.82%
5Y Revenue/Share
-17.04%
3Y Dividend/Share
67.64%
5Y Dividend/Share
-16.10%